Corvus Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $97.2M | $63.5M |
| FY2022 | — | $56.1M | $13.2M |
| FY2023 | — | $38.7M | $12.6M |
| FY2024 | — | $32.6M | $8.7M |
| FY2025 | — | $61.2M | $4.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $97.2M | $63.5M |
| FY2022 | — | $56.1M | $13.2M |
| FY2023 | — | $38.7M | $12.6M |
| FY2024 | — | $32.6M | $8.7M |
| FY2025 | — | $61.2M | $4.6M |